熱門資訊> 正文

Jade Biosciences计划公开发行预融资认购证

2026-06-04 04:26

JPMorgan發展中市場股票主動型ETF(JADE) 0

Jade Biosciences (JBIO) on Wednesday said it intends to offer shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants in an underwritten public offering.
The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the securities offered.
Proceeds will be used to support clinical trials, preclinical studies, manufacturing, research and development activities, and general corporate purposes.
Shares down 3% in after-hours trading.

More on Jade Biosciences, Inc.

Jade Biosciences: Strong Early Signal, But Still A Wait For Proof
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences: Caution Advised Before Clinical Trial Results
Seeking Alpha’s Quant Rating on Jade Biosciences, Inc.
Historical earnings data for Jade Biosciences, Inc.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。